News & Events

2005 Press Releases

Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca

San Diego, CA (December 15, 2005) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, is pleased to announce that AstraZeneca Pharmaceuticals LP (NYSE: AZN) has licensed access to its Target Informatics Platform™. Under the agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty's Target Informatics Platform (TIP™) and EVE™ Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs. Financial terms were not disclosed.

TIP is the world's first protein structure informatics system. Through the integration of protein structural data and ligand binding site analysis, TIP is designed to bridge the knowledge gap between the disciplines of bioinformatics and cheminformatics.

"We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts. We're confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.

For more information, please contact:

Steve Muskal

About Eidogen-Sertanty, Inc.

Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit

About AstraZeneca

AstraZeneca (NYSE:AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies in the world with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States, AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit: